| Literature DB >> 34630324 |
Long Bai1,2, Huihui Pan1, Yinjun Zhao3, Qingqing Chen1, Yu Xiang1, Xiaohang Yang2,3, Yimin Zhu1,2.
Abstract
Controlled ovarian hyperstimulation (COH) is the most common therapeutic protocol to obtain a considerable number of oocytes in IVF-ET cycles. To date, the risk factors affecting COH outcomes remain elusive. Growth differentiation factor 8 (GDF-8), a member of transforming growth factor β (TGF-β) superfamily, has been long discerned as a crucial growth factor in folliculogenesis, and the aberrant expression of GDF-8 is closely correlated with the reproductive diseases. However, less is known about the level of GDF-8 in IVF-ET patients with different ovarian response. In the present study, the potential risk factors correlated with ovarian response were explored using logistic regression analysis methods. Meanwhile, the expression changes of GDF-8 and its responsible cellular receptors in various ovarian response patients were determined. Our results showed that several factors were intensely related to poor ovarian response (POR), including aging, obesity, endometriosis, surgery history, and IVF treatment, while irregular menstrual cycles and PCOS contribute to hyperovarian response (HOR). Furthermore, POR patients exhibited a decrease in numbers of MII oocytes and available embryos, thereby manifesting a lower clinical pregnancy rate. The levels of GDF-8, ALK5, and ACVR2B in POR patients were higher compared with those in control groups, whereas the expression level of ACVR2A decreased in poor ovarian response patients. In addition, clinical correlation analysis results showed that the concentration of GDF-8 was negatively correlated with LH and estradiol concentration and antral follicle count. Collectively, our observations provide a novel insight of ovarian response-associated risk factors, highlighting the potential role of GDF-8 levels in ovarian response during COH process.Entities:
Keywords: ART; GDF-8; poor ovarian response; receptor; risk factor
Mesh:
Substances:
Year: 2021 PMID: 34630324 PMCID: PMC8499678 DOI: 10.3389/fendo.2021.708089
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Logistic regression analysis results of statistically significant variables.
| Grouping | Variables | B value | S.E. | Odds ratio (OR) (95% confidence interval) |
|
|---|---|---|---|---|---|
| Age ≥ 35 years old | 1.313 | 0.2 | 3.717 (2.509, 5.505) | 0.000 | |
| Poor response | Endometriosis Stage III | 1.562 | 0.678 | 4.768 (1.261, 18.021) | 0.021 |
| Endometriosis Stage IV | 1.643 | 0.49 | 5.173 (1.981, 13.507) | 0.001 | |
| Abortion times ≥4 | 1.218 | 0.625 | 3.383 (0.994, 11.503) | 0.051 | |
| Age ≥ 35 years old | −0.586 | 0.247 | 0.556 (0.343, 0.904) | 0.018 | |
| Hyper response (n=192) | Underweight | 0.695 | 0.35 | 2.003 (1.009, 3.977) | 0.047 |
| PCOS | 0.773 | 0.284 | 2.166 (1.241, 3.781) | 0.007 |
Laboratory results of different ovarian response groups.
| Age | Group | Number of MII oocytes | Fertilization rate | Valid embryos number |
|---|---|---|---|---|
| < 35 years old | Poor response (n=166) | 2.45 ± 1.28* | 0.640 ± 0.27 | 1.74 ± 1.01* |
| Normal response (n=409) | 6.05 ± 3.29 | 0.598 ± 0.24 | 3.396 ± 2.17 | |
| Hyper response (n=192) | 10.72 ± 5.40* | 0.539 ± 0.23* | 5.99 ± 4.35* | |
| ≥ 35 years old | Poor response (n=166) | 2.17 ± 1.25* | 0.626 ± 0.29 | 1.74 ± 1.02* |
| Normal response (n=409) | 6.25 ± 2.48 | 0.630 ± 0.19 | 3.61 ± 1.82 | |
| Hyper response (n=192) | 10.13 ± 5.22* | 0.563 ± 0.24 | 5.50 ± 3.55* |
*Means compared with the normal-response group, significant difference between the two groups exists.
Clinical outcomes of different ovarian response groups.
| Age | Group | Number of transplanted embryos | Number of cycle canceled and its rate (%) | Number of biochemical pregnancy and its rate (%) | Number of clinical pregnancy and its rate (%) | Number of abortion and its rate (%) | Number of live birth and its rate (%) |
|---|---|---|---|---|---|---|---|
| <35 years old | Poor response (n=166) | 1.50 ± 0.836 | 16 (15.39%) | 1 (1.14%) | 32 (40.32%)* | 3 (7.69%) | 33 (37.5%) |
| Normal response (n=409) | 1.68 ± 0.858 | 28 (17.07%) | 1 (0.74%) | 66 (48.53%) | 9 (13.64%) | 52 (38.24%) | |
| Hyper response (n=192) | 1.001 ± 0.983* | 73 (42.94%)* | 3 (3.09%) | 52 (53.61%) | 11 (21.15%) | 40 (41.24%) | |
| ≥35 years old | Poor response (n=166) | 1.54 ± 1.03* | 18 (18.75%) | 3 (3.85%) | 20 (25.64%)* | 7 (35%) | 10 (29.23%) |
| Normal response (n=409) | 2.17 ± 1.08 | 5 (13.89%) | 2 (6.45%) | 18 (58.065%) | 5 (27.78%) | 12 (38.71%) | |
| Hyper response (n=192) | 1.67 ± 1.08* | 4 (13.33%) | 1 (3.85%) | 7 (26.92%)* | 1 (14.29%) | 5 (19.23%)* |
*Means compared with the normal-response group, significant difference between the two groups exists.
Figure 1The expression changes of GDF-8 and its responsible receptors in different ovarian response patients. (A, B) The accumulation level changes of GDF-8 in serum and follicular fluid obtained from different ovarian response patients were determined by ELISA. (C–F) The protein expression level changes of GDF-8 and its responsible receptors (ALK5, ACVR2A, and ACVR2B) were examined in different ovarian response patient granulosa cells using western blot. The data were analyzed by the two-sample t test assuming unequal variances. P < 0.05 was considered statistically significant. POR (n=30), poor ovarian response. HOR (n=33), hyper ovarian response. Normal, n=33.
Figure 2The correlation analysis of GDF-8 and clinical ovarian response patients. (A–C) The correlation analysis of GDF-8 levels with hormone concentration, including FSH, LH, and estradiol. (D) The correlation analysis of GDF-8 levels with antral follicle count. (E) The correlation analysis of GDF-8 levels with AMH levels. The data were analyzed by the two-sample t test assuming unequal variances. P < 0.05 was considered statistically significant. n=51.